Present

Suzanne Olbricht, MD, FAAD, President
Theodore Rosen, MD, FAAD, Vice President
Henry W. Lim, MD, FAAD, Immediate Past President
Barbara M. Mathes, MD, FAAD, Secretary-Treasurer
Marta J. Van Beek, MD, MPH, FAAD, Assistant Secretary-Treasurer
George J. Hruza, MD, MBA, FAAD, President-Elect
Jane M. Grant-Kels, MD, FAAD, Vice President-Elect
Abby S. Van Voorhees, MD, FAAD
Diane S. Berson, MD, FAAD
Linda F. Stein Gold, MD, FAAD
Mark D. Kaufmann, MD, PhD, FAAD
Robert S. Kirsner, MD, PhD, FAAD
Gary S. Wood, MD, FAAD
Juliet A. Zitelli, MD, FAAD
Janet G. Hickman, MD, FAAD
Kimberly J. Butterwick, MD, FAAD
Marta J. Van Beek, MD, MPH, FAAD
George J. Hruza, MD, MBA, FAAD
Robert A. Weiss, MD, FAAD
Scott M. Dinehart, MD, FAAD
Seema R. Desai, MD, FAAD
Valerie D. Callender, MD, FAAD
Terrence A. Cronin, Jr., MD, FAAD
Danette D. Bentley, MD, FAAD, Young Physician Board Observer
Mauricio Goihman-Yahr, MD, International Board Observer

Not Present

Erin Boh, MD, PhD, FAAD
Marc D. Brown, MD, FAAD
Heidi Wat, MD, Residents/Fellows Board Observer

Incoming Board Members

Bruce H. Thiers, MD, FAAD, Incoming President-Elect
Susan C. Taylor, MD, FAAD, Incoming Vice President-Elect
Daniel D. Bennett, MD, FAAD, Incoming Assistant Secretary-Treasurer
Adelaide Hebert, MD, FAAD, Incoming Class of 2023
Alexander Miller, MD, FAAD, Incoming Class of 2023
Lawrence Green, MD, FAAD, Incoming Class of 2023
Cyndi Yag-Howard, MD, FAAD, Incoming Class of 2023
Travis W. Blalock, MD, FAAD, Incoming Young Physician Board Observer
Emily O. McLean, MD, Incoming Resident-Fellow Board Observer

Speakers / Guests

Sabra Sullivan, MD, PhD, FAAD, Chair, Council on Government Affairs and Health Policy
Kathryn Schwarzenberger, MD, FAAD, Physician Editor Dermatology World
Janet A. Fairley, MD, FAAD, Incoming President, Dermatology Foundation
Daniel Siegel, MD, MS, FAAD, Member, Professionalism & Ethics Committee
Anthony Bennett, Managing Director, RedSky Strategy
Craig A. Elmets, MD, FAAD, Chair, Council on Science and Research and the Guidelines Workgroup
CALL TO ORDER
Suzanne Olbricht, MD, FAAD, President and presiding, called the meeting of the Board of Directors of the American Academy of Dermatology to order at 8:00 a.m. (Eastern) on Monday, March 4, 2019. She welcomed the incoming officers and directors and guests.

QUORUM
Barbara M. Mathes, MD, FAAD, Secretary-Treasurer declared that a quorum was present for the transaction of business.

ORDER OF BUSINESS/INTRODUCTORY MATTERS
Antitrust Compliance Policy, Fiduciary Obligations, and Note Taking
Dr. Mathes referred the Board members to the background materials regarding the AAD/Antitrust Compliance Policy and note taking during meetings and reminded them about the importance of following their fiduciary obligations, including maintaining confidentiality and declaring conflicts of interest.

Disclosure of Conflicts of Interest and Code of Conduct
The Board members’ disclosures of potential conflicts of interest and code of conduct were circulated. Dr. Mathes asked Board members to update their disclosures and to declare any other
actual or potential conflicts of interest with respect to specific agenda items for this meeting. None were declared.

Separate Order of Business
Dr. Mathes reminded the Board members that they would be following the American Institute of Parliamentarians Standard Code of Parliamentary Procedure (formerly Sturgis Code of Parliamentary Procedure), and that it is essential that the AAD follow the order of business and observe corporate formalities necessary to ensure the separateness of the two organizations.

AAD OFFICER AND DIRECTORS REPORTS
President’s Report
Dr. Olbricht reported that she created two ad hoc task forces, one on the search for an interim Executive Director and one on the search for the permanent Executive Director/CEO to replace Ms. Weiss, who recently resigned to take a position with another medical specialty society. She also reported on the creation of the Ad Hoc Task Force on DataDerm Sustainability and the Skin Cancer/Skin of Color Work group; the status of key AAD/A initiatives; recent meetings and events that she and other leaders had attended; and recent advocacy successes. Dr. Olbricht next reported on the revamped AccessDerm (teledermatology) program and the Moshi 2020 Conference on tropical diseases. She concluded her regular report by thanking the officers and the Board for their service and staff for their outstanding work during her presidency. She gave a special thanks to Dr. Mathes for her 7+ years of service as the Secretary-Treasurer and Assistant Secretary-Treasurer, as well as Ms. Weiss for her service as Executive Director and CEO.

Dr. Olbricht then provided remarks on the effect that artificial intelligence will have on medicine generally and the specialty of dermatology in particular.

Secretary-Treasurer’s Report
Twelve-Month Year-to-Date Financial Report Ending December 31, 2018
Dr. Mathes presented the Twelve-Month Year-to-Date Financial Report Ending December 31, 2018. She first reported on the key 2018 initiatives and accomplishments. Dr. Mathes then reported that the 2019 budget has a projected surplus of $113,192 on $51.4 million in revenues. She also reported on the unofficial, unaudited financial results for end of fiscal year 2018, noting that the final audited results will be presented at the May Board meeting. She discussed specific revenue and expense line items and reported an unofficial surplus of $1.88 million for 2018. She briefly reported on the status of AAD/A investments and the Reserve Income Fund (RIF). She noted that the RIF balance was short of the required balance, but this was permissible under the revised policy allowing the Endowment Fund balance to be considered in assessing RIF compliance. She thanked the Board for the opportunity to serve as Secretary-Treasurer and Assistant Secretary Treasurer for the past seven years and thanked staff for all of their great work in support of her efforts. She also discussed the importance of the Secretary-Treasurer position in the AAD/A governance structure.

After discussion, a motion was made and duly seconded to approve the Twelve-Month Year-to-Date Financial Report Ending December 31, 2018 for information only.

ACTION: Approved

Long-Term Financial Retreat
Dr. Mathes presented the Long-Term Financial Retreat report. She stated that purpose of the retreat was to explore new revenue sources to supplement current revenue streams, including through license fees/royalties for AAD educational products. The attendees discussed the need to think creatively and possibly remove policies or practices that are inhibiting new revenue streams. Daniel D. Bennett, MD, FAAD, incoming Assistant Secretary-Treasurer will be taking responsibility...
for implementing suggestions and ideas discussed at the retreat.

A motion was made and duly seconded to approve the Long-Term Financial Retreat report for information only.

**ACTION:** Approved

**Executive Director Report**

Elaine Weiss referred the Board to her written report and highlighted several issues in her verbal report. She summarized the year’s key initiatives, successes, and challenges, including the move to Rosemont, meetings, education, Practice Management Center, DataDerm, AccessDerm, election reforms, and various advocacy wins.

She thanked the Board for the opportunity to serve as the AAD/A Executive Director & CEO and expressed her gratitude to the staff for their great work and support.

She then presented a moving video tribute to Dr. Olbricht in honor of her successful year as AAD/A President.

**Dermatology Foundation Report**

Janet Fairley, MD, FAAD, Dermatology Foundation Incoming President, presented the Dermatology Foundation Report. She thanked the Board for its support over the years and summarized the purpose, activities, and accomplishments of the Foundation in promoting and supporting research on dermatologic conditions and treatments in the last year. She noted that the Foundation recently started a new planned giving program called Visionary Society.

**Relaunch of AAD.org**

Ms. Katie Domanowski and Mr. Erik Horn presented their Relaunch of AAD.org report. Ms. Domanowski stressed that the goal was to put the needs of members and other users first. She discussed the problems with the current website and the plan for addressing them. She noted that the first step was to conduct surveys, focus groups, and other activities to better understand user concerns and needs and will do extensive usability and concept research and testing to guide the redesign process. She presented the results of the research that had been done so far. She noted that the new site will have:

- Improved tools for quality control
- Tightened governance structure
- Better search management
- New content management system

She said the target re-launch date is Fall 2019.

**International Board Observer Report**

Mauricio Goihman-Yahr, MD referred the Board to his written report for information only. He noted that the Academy should be looking for ways to permit international dermatologists to practice medicine in the United States or other countries to which they migrate.

**Young Physicians Board Observer Report**

Danette D. Bentley, MD referred the Board to her written report for information only. She thanked the Board for the opportunity to serve as the Young Physician representative on the Board.

A motion was made and duly seconded to accept the reports of the Academy Officers, the Dermatology Foundation, the Relaunch of the AAD.org, and Board Observers as presented.
ACTION: Approved

Private Equity and the Healthcare Environment
Dr. Olbricht introduced David Sheinfeld, Managing Director at Horizon Business Advisors LLC. Mr. Sheinfeld gave a report on private equity in the healthcare environment. He first provided background on how private equity works generally and then on the emergence of private equity in the medical field. He discussed both the benefits and costs/risks of selling/partnering with private equity firms and answered several questions from the Board.

The meeting was recessed and the AADA Board meeting was convened at 11:32 a.m. (Eastern).

The meeting was reconvened at 11:45 a.m. (Eastern).

Life in Practice/Membership Trends
Ms. Cindy Kuhn and Ms. Rosie Balk presented the Life in Practice/Membership Trends report. Ms. Balk noted the report was based on a survey of two sample groups: 7800 randomly-selected, demographically representative U.S. Fellows and a boost sample group of 870 members employed in dermatology groups owned by private equity entities. She presented the results of the survey to demonstrate the current state of dermatology practice, dermatologist happiness, and views on non-physician clinicians and supervision.

A motion was made and seconded to accept the Life in Practice/Membership Trends report for information only.

ACTION: Approved

Sunscreen Report
Henry W. Lim, MD, FAAD presented the Sunscreen Report. He updated the Board on oxybenzone and octinoxate bans in Hawaii and Key West and proposed legislation in California and Florida. He noted that the science does not clearly show that sunscreens with these chemicals is contributing to coral reef bleaching; rather numerous other factors, including climate change are much more important factors in damaging coral reefs.

Dr. Lim then gave a report on the FDA proposed sunscreen rule, which was issued on February 26, 2019. The proposed rule recognizes the importance of sunscreen as one component in a comprehensive sun protection strategy. It notes that the proposed rule is one step towards issuing a final sunscreen monograph as required by the Sunscreen Innovation Act of 2014. The final rule and monograph are expected to be issued in the Fall of 2019. Dr. Lim then provided more details on the proposed rule and answered questions from the Board.

A motion was made and duly seconded to accept the Sunscreen Report for information only

ACTION: Approved

HEARD FROM THE FIELD
Dr. Olbricht invited Board members to raise issues of concern that they were hearing about in the field. The comments focused on audiovisual issues during presentations and exhibit hall hours during the Annual Meeting.
**AAD UNFINISHED BUSINESS**

265 Ad Hoc Task Force on Strategic Corporate Positioning
266 Branding Update – AAD Brand Story
268 Abby Van Voorhees, MD, FAAD and Mr. Anthony Bennett from RedSky Strategy presented the Corporate Positioning Branding Update. They noted that the charge of the ad hoc task force is to review and come up with recommendations for updating the AAD/A brand. They discussed the steps that had been taken so far to evaluate the impressions of members and others about the current AAD/A brand through surveys and focus groups and summarized the results. They described the next step as the design phase in which they would develop a narrative around the AAD/A brand and a masterbrand design and architecture and then test it with members and others. They discussed the elements and themes of a brand narrative. They indicated that the manifesto for the rebranding initiative would focus on members as the Academy’s source of power and inspiration.

278 After discussion, a motion was made and duly seconded to approve and authorize the Ad Hoc Task Force to move forward with developing the brand narrative and to take the other steps discussed in the report.

**ACTION:** Approved

284

**Journal of the American Academy of Dermatology International (JAADI)**
286 Marta J. Van Beek, MD, MPH, FAAD presented the JAAD International report for information only and highlighted several issues on the development of the international edition. She reminded the Board that it approved moving forward with concept at its November 2018 meeting. She then presented the more detailed proposal for this international, open-access edition of JAADI. She noted that there is no financial exposure because of the online, open-access nature of the journal and that the target launch date is 2020.

293 After discussion, a motion was made and duly seconded to approve proceeding with the plan as proposed and signing the agreement with Elsevier to begin publishing JAADI.

**ACTION:** Approved

298

**Council on Education**
299 AAD04 (A-18) Advisory Board Resolution: Position Statement on Accreditation Council for Graduate Medical Education (ACGME) Dermatology Residency and Fellowship Training
301 Exclusivity for ACGME Dermatology Resident and/or Fellows
302 Dr. Mathes presented the Council on Education report. She stated at its November 3, 2018 meeting, the AAD Board of Directors referred the following Advisory Board resolution to the Council on Education with a directive to draft a position statement.

**RESOLVED,** that the AAD issue a position statement, that is forwarded to Residency Training Program Directors and Department Chairs, stating that terms such as “residency training” and “fellowship training” be reserved for physicians as described by the Accreditation Council for Graduate Medical Education (ACGME); and be it further

**RESOLVED,** that the AAD/A as the pre-eminent teaching organization for dermatologists in the United States opposes the teaching of Nurse Practitioners and Physician Assistants alongside physicians in ACGME accredited dermatology residency programs using titles such as “dermatology residencies” and “dermatology fellowships.”

AAD BOD MINUTES – DRAFT – 30 DAYS – March 25, 2019
Testimony was only heard in support of the resolution. It was highlighted how these titles may mislead the public. Some expressed that there still needs to be a way for non-physicians to be credentialed. Members also discussed how the AAD’s truth-in-advertising position statement is in the process of being updated and may help address several of these issues.

The Board discussed the draft position statement set forth in the background materials at pp. 27-28. After discussion, a motion was duly made and seconded to refer this position statement back to Council on Education to make it clearer that the terms residency and fellowship should only be used for physicians training programs and should not be used for non-physician training programs.

**ACTION:** Approved

**CONSENT AGENDA**

**Leadership Development Steering Committee**

Seemal R. Desai, MD, FAAD presented the Leadership Development Steering Committee report for information only. He highlighted the strategic goals, objectives, and successes of the Leadership Institute and reported on the results of a survey of individuals who have participated in the Institute’s programs.

A motion was made and duly seconded to approve Leadership Development Steering Committee report for information only.

**ACTION:** Approved

**AAD NEW BUSINESS**

**Ad Hoc Task Force on Data Collection Platform and Registries**

Dr. Van Beek presented the AHTF on Data Collection Platform and Registries report. She discussed the number of participants, patients, patient visits, and other data collected by the registry to date. She then gave examples of the types of diagnoses that can now be studied from the registry data. She also discussed DataDerm’s activities as a qualified clinical data registry and qualified registry under the Merit-Based Incentive Payment System (MIPS); data standardization and EHR recognition efforts; data governance; and 2019 priorities.

A motion was made and duly seconded to approve the Ad Hoc Task Force on Data Collection Platform and Registries report for information only.

**ACTION:** Approved

**Ad Hoc Nominating Committee**

Theodore Rosen, MD, FAAD stated that the Ad Hoc Nominating Committee proposed the following two candidates to the Board for election to serve as a Board representative on the Nominating Committee. This year the candidates were from the East / Northeast Region. The nominees were:

Marc D. Brown, MD, FAAD
Amit Garg, MD, FAAD

The Board discussed the two candidates and voted by closed ballot. Dr. Mathes announced that the new Board representative on the Nominating Committee would be Dr. Brown.
Dr. Rosen noted that the Advisory Board met the day before, Sunday, March 3, and elected Kevin Crawford, MD, FAAD to serve as the Advisory Board member representative on the Nominating Committee.

**Bylaws Committee**

**AAD Proposed Bylaws Amendment to Article VI-Nominating Committee Composition**

Mark D. Kaufmann, MD, FAAD presented the Bylaws Committee report. He stated the Bylaws Committee met via conference call on December 4, 2018 to discuss the proposed bylaws amendment from Ad Hoc Task Force on Election Oversight.

AAD BYLAWS

ARTICLE VI

Board of Directors

Section 3. Nomination and Election

(a) The Nominating Committee shall consist of six (6) members and a Chair **who shall be voting members, and one (1) former president who shall be a non-**; all seven (7) of whom shall be voting members of the Committee. **All shall be and Fellows of the Academy (or Life or Honorary Members who have been Fellows) in good standing. Two (2) members of the Nominating Committee shall be elected by the Board of Directors; two (2) shall be elected by the Advisory Board; and two (2) shall be elected by the membership by electronic and/or other written ballot. Each member of the Nominating Committee except the Chair shall serve a term of two (2) consecutive election cycles, provided, however, that the terms of these members shall be staggered so that in each year the Board of Directors and the Advisory Board shall each elect one (1) member for a term of two (2) election cycles, and the membership shall elect one (1) member for a term of two (2) election cycles from two (2) candidates presented by the Nominating Committee. At the conclusion of each election cycle, the Nominating Committee shall elect one (1) member who has completed two (2) election cycles on the Committee to serve as Chair of the Committee for the next election cycle. Candidates for membership on the Nominating Committee shall be selected with due regard for geographic representation. No incumbent member of the Board of Directors may serve on the Nominating Committee. No person may serve consecutive terms on the Nominating Committee. Members of the Nominating Committee shall not be eligible for election to office or to the Board of Directors in the election following any election for which they have served on the Nominating Committee. The former president shall serve an automatic one-year appointment on the Nominating Committee upon completion of his/her appointment on the Ad Hoc Task Force on Election Oversight. No other former president shall, through election or appointment, serve on the Nominating Committee.**

A motion was made and duly seconded to approve the bylaws amendment to modify the Nominating Committee’s composition as presented and send the proposed amendment to the membership for vote with a footnote that any former president who is serving or nominated to serve on the Nominating Committee prior to the effective date of this amendment shall be eligible to serve on the Nominating Committee in addition to the one former president allowed under this amendment.

**ACTION: Approved**

A motion was made and duly second to include a Board recommendation to approve the bylaws amendment in the ballot book.

**ACTION: Approved**

AAD BOD MINUTES – DRAFT – 30 DAYS – March 25, 2019
Amendment to AR on Bylaws Committee

Dr. Kaufman reported that the Bylaws Committee recommended the Board amend the Administrative Regulation on the Bylaws Committee to clarify that the Bylaws Committee does not make recommendations whether the membership should approve or not approve Bylaws amendments, but rather only determines whether Bylaws amendments are permissible based on the criteria listed in the Administrative Regulation.

A motion was made and duly seconded to approve the amendments to the Administrative Regulation on the Bylaws Committee.

**ACTION:** Approved by the required 2/3 vote

Confirmation of Secretary-Treasurer

Dr. Olbricht noted that the Secretary-Treasurers must be affirmed by every new AAD Board.

A motion was made and duly seconded to confirm Marta J. Van Beek, MD, MPH, FAAD as Secretary-Treasurer and Daniel D. Bennett, MD, FAAD as Assistant Secretary-Treasurer for the 2019-2020 AAD Board of Directors term effective at the close of the 2019 Annual Meeting.

**ACTION:** Approved

AAD Annual Organizational Resolution

Dr. Mathes stated that the Annual Organizational resolution, which was included in the Board’s background materials, was a housekeeping matter that allows the officers and staff to transact business on behalf of the Academy.

A motion was made and duly seconded to adopt the AAD Annual Organizational Resolution as presented.

**ACTION:** Approved

AAD STRATEGIC DISCUSSION

Ad Hoc Task Force on Reimagining the Summer Meeting

Allison Vidimos, MD, RPh, FAAD presented the report of the Ad Hoc Task Force on Reimagining the Summer Meeting. She discussed the various elements of the proposal, including Innovation Day, the Derm Experience Hub (an interactive learning and networking area), Derm Shark Tank, and Derm 365 (a virtual communications platform connected with the meeting), as well as the welcome, faculty, and other receptions. She also discussed the budget implications of the various elements and the next steps—i.e., to establish a new meeting brand and create a task force to further develop the proposed concepts, budget, and funding sources. The Board provided feedback on the various concepts and whether it felt they were worth further development or not.

A motion was made and duly seconded to approve the report on Reimagining the Summer Meeting, including the moving forward with creating a meeting brand and a task force to further develop the major new components for the meeting, taking into account the Board’s feedback, with a goal of implementing such concepts beginning with the 2020 Academy Summer Meeting.

**ACTION:** Approved
The meeting was recessed and the AADA Board meeting was convened at 3:12 p.m. (Eastern).

The meeting reconvened at 3:17 p.m. (Eastern).

AAD NEW BUSINESS

Council on Science & Research

Position Statement: Sexual and Gender Minority Health in Dermatology

Klint Peebles, MD, FAAD presented the Position Statement: Sexual and Gender Minority Health in Dermatology from the Council on Science & Research report, which was set forth at pp. 115-117 of the background materials. Dr. Peebles provided background on the need for the statement and summarized the content of the statement.

A motion was made and duly seconded to approve the Position Statement: Sexual and Gender Minority Health in Dermatology.

ACTION: Approved

Psoriasis Clinical Guidelines

Craig A. Elmets, MD, FAAD presented the Psoriasis Clinical Guidelines from the Council on Science & Research report. He reported that this is the third section of these guidelines that has come before the Board for approval, with biologics and co-morbidities having been approved at previous meetings. He described the process for creating and vetting the guidelines, including member comments and noted that the phototherapy section will be published in a forthcoming issue of the Journal of the American Academy of Dermatology.

A motion was made and duly seconded to approve the draft Joint American Academy of Dermatology/National Psoriasis Foundation (AAD-NPF) guidelines of care for the management and treatment of psoriasis with phototherapy.

ACTION: Approved

Joint Guideline on Reconstruction after Skin Cancer Resection

Dr. Van Beek presented an update on the Joint Guideline on Reconstruction after Skin Cancer Resection from the Council on Science & Research report. She provided the background on the Memorandum of Understanding (MOU) with the other societies involved in the joint working group, including the American Society of Plastic Surgery as the lead group, the procedures that will be followed to develop the guidelines, and the questions that will be addressed. She noted that the process is on a fast track and discussed need for an expedited timeline for approval, essentially requiring Board approval of the guidelines before the next Board meeting in May.

A motion was made and duly seconded to approve sending an email ballot on the Joint Guideline on Reconstruction after Skin Cancer Resection to the Board prior to the 90-day deadline of April 28, 2019 as directed by the MOU.

ACTION: Approved

Professionalism and Ethics Committee

Position Statement on Discount Cosmetic Surgery Networks

Dr. Mathes referred the Board to the supplemental information and presented the recommendations from the Professionalism and Ethics Committee (PEC). She stated the first recommendation is to sunset the Position Statement on Discount Cosmetic Surgery Networks.
A motion was made and duly seconded to approve sunsetting the Position Statement on Discount Cosmetic Surgery Networks.

**ACTION:** Approved

### Board Governance Policy on Conduct at AAD/A Meetings and other AAD/A Activities

Dr. Mathes stated the next PEC recommendation is to approve the newly-created Board Governance Policy (BGP) on Conduct at the AAD/A Meetings and other AAD/A Activities.

Dr. Olbricht charged the PEC with reviewing the Academy’s current harassment policy, identify gaps and propose a new, comprehensive policy for the Board to review and ratify. The PEC formed a workgroup to tackle this task and created the draft policy. The policy was presented to and approved by the full Committee.

A motion was made and duly seconded to approve the Board Governance Policy on Conduct at AAD/A Meetings and other AAD/A Activities.

**ACTION:** Approved

### AAD/A Committee Member Copyright Assignment, Confidentiality, and COI Agreement

Daniel M. Siegel, MD, MS, FAAD presented the AAD/A Committee Member Copyright Assignment, Confidentiality and COI Agreement. He noted that this agreement was a housekeeping matter to ensure that committee members assigned their copyright interest in committee work product to the Academy or Association and reminds them of their obligations to maintain confidentiality and disclose conflicts of interest.

A motion was made and duly seconded to approve the AAD/A Committee Member Copyright Assignment, Confidentiality, and COI Agreement.

**ACTION:** Approved

### Administrative Regulation on Disclosure of Potential Conflict of Interest

Dr. Siegel then presented the Committee’s recommendations to the Administrative Regulation on Disclosure of Potential Conflict of Interest (COI). He first discussed the language necessary to comply with Accreditation Council for Continuing Medical Education (ACCME) requirements.

A motion was made and duly seconded to accept the ACCME-related revisions to the COI policy.

**ACTION:** Approved

The Board discussed the remainder of the proposed changes and indicated a need to expand the types of practice models that need to be disclosed (not just private equity) and the name of the employer. They also indicated that the definition of financial interest needs to be expanded to include employment relationships; but opposed the inclusion of financial ranges.

A motion was made and duly seconded to refer the remainder of the changes to the Administrative Regulation on Disclosure of Potential Conflict of Interest back to the PEC to add employer and practice model to the disclosure requirements, and not to include financial ranges.

**ACTION:** Approved
Ad Hoc Task Force on Modernizing Clinical Guidance
Terrence A. Cronin, Jr., MD, FAAD presented the Ad Hoc Task Force (AHTF) on Modernizing Clinical Guidance report. He reminded the Board of the mission statement of the AHTF and presented the recommendations for streamlining the guideline process. The changes were presented on pp. 239-248 of the background materials.

A motion was made and duly seconded to amend the proposed changes so that members of Guideline Work Group who are already conflicted can take on additional conflicts during their service on a guideline work group, but those that are non-conflicted members of the Work Group may not acquire new conflicts relevant to the charge of the Work Group until the guideline is published. A non-conflicted member acquiring new relevant conflicts during the course of guideline development will be removed and replaced by a non-conflicted member. The appointee removed for this reason will forfeit authorship role, even if s/he contributed significantly in developing the clinical guideline.

**ACTION:** Approved

A motion was made and duly seconded to approve the changes to the Administrative Regulation on Evidenced-Based Clinical Practice Guidelines as amended.

**ACTION:** Approved by the required 2/3 vote

The Board moved into Executive Session at 5:45 p.m. (Eastern)

The Board moved out of Executive Session at 6:00 p.m. (Eastern)

Note that the minutes of the Executive Session are kept in the confidential files of the Executive Office and legal counsel.

**ADJOURNMENT**

There being no further business, Dr. Olbricht adjourned the AAD Board of Directors Meeting at 6:00 p.m. (Eastern).

Respectfully Submitted,

Barbara M. Mathes, MD, FAAD
Secretary-Treasurer